TABLE 2.

Susceptibility profiles of the bacterial strains included in this studya

StrainMIC (μg/ml) (susceptibility rating) for indicated drug
TGCMINGENTOBCIPCHLPIPCAZFEPIPMMEM
D540.1250.125 (S)0.25 (S)0.75 (S)0.25 (S)0.125 (S)16 (S)4.0 (S)1.5 (S)0.125 (S)0.25 (S)
A242.032 (R)64 (R)4.0 (S)256 (R)16 (I)16 (S)>256 (R)16 (I)0.38 (S)1.0 (S)
A24 + PABN2.02.0 (S)48 (R)3.0 (S)128 (R)12 (I)3.0 (S)96 (R)3.0 (S)0.032 (S)0.094 (S)
A24A2.012 (I)256 (R)3.0 (S)256 (R)96 (R)12 (S)>256 (R)12 (I)0.125 (S)0.75 (S)
A24B2.016 (R)256 (R)4.0 (S)256 (R)96 (R)12 (S)>256 (R)12 (I)0.125 (S)0.75 (S)
A24C6.016 (R)512 (R)6.0 (I)256 (R)96 (R)16 (S)>256 (R)16 (I)0.19 (S)0.75 (S)
A24Db2432 (R)256 (R)16 (R)512 (R)16 (I)24 (I)>256 (R)16 (I)0.50 (S)2.0 (S)
A24D + PABN2.08.0 (I)96 (R)8.0 (I)128 (R)4.0 (S)1.0 (S)32 (R)1.0 (S)0.064 (S)0.094 (S)
B464.00.25 (S)8.0 (I)24 (R)128 (R)32 (R)256 (R)96 (R)>256 (R)1.5 (S)4.0 (I)
B46 + PABN1.00.25 (S)4.0 (S)16 (R)128 (R)8.0 (S)256 (R)8.0 (S)128 (R)0.25 (S)0.25 (S)
C75162.0 (S)128 (R)16 (R)512 (R)32 (R)48 (I)192 (R)>256 (R)1.5 (S)4.0 (I)
C75 + PABN4.01.0 (S)16 (R)6.0 (I)256 (R)8.0 (S)8.0 (S)8.0 (S)16 (I)0.125 (S)0.125 (S)
  • a TGC, tigecycline; MIN, minocycline; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; CHL, chloramphenicol; PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; R, resistant; S, susceptible; I, intermediate.

  • b An isolate that underwent tigecycline in vitro exposure.